Eton Pharmaceuticals, Inc.(ETON)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated .

Eton Pharmaceuticals, Inc. (ETON) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ETON at 67.5/100 on a 32-signal composite quality model, placing it at rank #364 of 2,961 stocks — the top 25% of the AI-ranked universe. ETON scores in the top quartile across revenue growth (95.5), balance sheet strength (88.4), profitability (75.3). Areas of concern include revenue scale (16.6), which score below median versus the broader universe. Shareholder dilution risk is elevated at 20.8/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Eton Pharmaceuticals, Inc. reports quarterly revenue of $37.6M, net income of $11.6M, free cash flow of $7.3M. Top institutional holders of ETON by reported 13-F value include Opaleye Management, EcoR1 Capital, BlackRock, based on the most recent SEC filings. ETON trades on the Nasdaq exchange and files with the SEC under CIK 1710340. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ETON daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Eton Pharmaceuticals, Inc. directly from SEC EDGAR.

AI Quality Score

67.5/100

AI Rank

#364

Revenue

$37.6M

Net Income

$11.6M

Free Cash Flow

$7.3M

ETON key financials by period

Eton Pharmaceuticals, Inc. reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodFormRevenueNet incomeOperating margin
FY 202510-K$80.0M$-4.6M-1.1%
FY 202410-K$39.0M$-3.8M-6.7%
FY 202310-K$31.6M$-936.0K-3.8%
FY 202210-K$21.3M$-9.0M-38.9%
FY 202110-K$21.8M$-2.0M-6.9%
FY 202010-K$39.0K$-28.0M

Institutions holding ETON

Institutional investors reporting a position in Eton Pharmaceuticals, Inc. on SEC Form 13F.
InstitutionSharesValueReported
Opaleye Management2,860,000$103.5M2026-06-30
EcoR1 Capital2,171,938$78.6M2026-06-30
BlackRock1,895,833$68.6M2026-06-30
Nantahala Capital Management1,175,951$42.6M2026-06-30
VANGUARD CAPITAL MANAGEMENT976,570$35.4M2026-06-30
MORGAN STANLEY767,972$27.8M2026-06-30
STATE STREET701,786$25.4M2026-06-30
GEODE CAPITAL MANAGEMENT652,303$23.6M2026-06-30
OBERWEIS ASSET MANAGEMENT501,600$18.2M2026-06-30
National Philanthropic492,112$17.8M2026-06-30